Abstract
The biological functions of angiotensin (Ang) II are mediated by two Ang II receptors, designated type 1 receptor (AT1R) and type 2 receptor (AT2R). Most of the cardiovascular effects of Ang II are mediated by AT1R that is expressed widely in the body. The expression of AT1R is up-regulated in cardiovascular lesions, and is regulated by many endogenous bioactive substances and drugs. The AT2R is generally considered to antagonize the effects of AT1R, but its precise function remains enigmatic and controversial, particularly in humans. The expression of AT2R is low in normal adult animals, but AT2R expression is up-regulated in cardiovascular lesions. The dynamic regulation of AT1R and AT2R expression suggests an active involvement of Ang II receptors in the development of cardiovascular diseases such as atherosclerosis, heart failure, chronic kidney diseases and cerebrovascular diseases. Further clarification of gene regulatory mechanisms of Ang II receptors may identify potential targets for the development of novel therapeutics for cardiovascular diseases.
Keywords: Angiotensin II, type 1 receptor, type 2 receptor, gene expression, gene regulation.
Current Pharmaceutical Design
Title:Regulation of Angiotensin II Receptor Expression
Volume: 19 Issue: 17
Author(s): Toshihiro Ichiki
Affiliation:
Keywords: Angiotensin II, type 1 receptor, type 2 receptor, gene expression, gene regulation.
Abstract: The biological functions of angiotensin (Ang) II are mediated by two Ang II receptors, designated type 1 receptor (AT1R) and type 2 receptor (AT2R). Most of the cardiovascular effects of Ang II are mediated by AT1R that is expressed widely in the body. The expression of AT1R is up-regulated in cardiovascular lesions, and is regulated by many endogenous bioactive substances and drugs. The AT2R is generally considered to antagonize the effects of AT1R, but its precise function remains enigmatic and controversial, particularly in humans. The expression of AT2R is low in normal adult animals, but AT2R expression is up-regulated in cardiovascular lesions. The dynamic regulation of AT1R and AT2R expression suggests an active involvement of Ang II receptors in the development of cardiovascular diseases such as atherosclerosis, heart failure, chronic kidney diseases and cerebrovascular diseases. Further clarification of gene regulatory mechanisms of Ang II receptors may identify potential targets for the development of novel therapeutics for cardiovascular diseases.
Export Options
About this article
Cite this article as:
Ichiki Toshihiro, Regulation of Angiotensin II Receptor Expression, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170007
DOI https://dx.doi.org/10.2174/1381612811319170007 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Azoles in Cancer Prevention and Treatment: Present and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Sudden Unexpected Death in Infancy (SUDI) — The Role of the Pathologist
Current Pediatric Reviews Identification of Novel NaV1.7 Antagonists Using High Throughput Screening Platforms
Combinatorial Chemistry & High Throughput Screening Effects of PPARγ Agonists against Vascular and Renal Dysfunction
Current Molecular Pharmacology Irritable Bowel Syndrome and Drospirenone-Containing Oral Contraceptives; A Comparative-Safety Study
Current Drug Safety Myocardial Insulin Resistance and Cardiac Complications of Diabetes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Current Topics in Medicinal Chemistry Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Endothelial Cell Senescence and Inflammaging: MicroRNAs as Biomarkers and Innovative Therapeutic Tools
Current Drug Targets Architecture and Conservation of the Bacterial DNA Replication Machinery, an Underexploited Drug Target
Current Drug Targets Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
Current Pharmaceutical Design Biomarkers Associated with Bleeding Risk in the Setting of Atrial Fibrillation
Current Medicinal Chemistry Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design Forkhead Genes: Their Role and Impact on Ocular Developmental Diseases
Current Genomics Is there Any Correlation Between Binding and Functional Effects at the Translocator Protein (TSPO) (18 kDa)?
Current Molecular Medicine Advances in Design and Development of Inhibitors of Nitric Oxide Synthases
Current Enzyme Inhibition Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Ibogaine in the Treatment of Substance Dependence
Current Drug Abuse Reviews Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets